Jubilant Life Sciences gets USFDA nod for Indomethacin capsules

Published On 2015-10-09 06:27 GMT   |   Update On 2015-10-09 06:27 GMT
Advertisement
NEW DELHI: Drug firm Jubilant Life Sciences has received approval from the US health regulator to market Indomethacin capsule used for treating pains.

In a BSE filing, Jubilant Life Sciences said it "received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (USFDA) for Indomethacin ER Capsule 75mg, which is a non-steriodal anti-inflammatory drug used for treatment of pain
Advertisement

Jubilant Life Sciences said as on June 30, 2015, it had a total of 815 filings for formulations of which 389 have been approved in various regions globally.

"This includes 72 ANDAs filed in the US, of which 38 have been approved and 46 Dossier filings in Europe," it added.





Jubilant Life Sciences Limited is a Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company provides offerings of Pharmaceutical and Life Sciences products and services across the value chain. It has 10  manufacturing facilities in India, US and Canada and a team of about 6,000 multicultural people across the globe.



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News